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Original Article
The frequency of heparin induced thrombocytopenia in patients
undergoing elective cardiac bypass surgeries
Natasha Ali,1 Bushra Moiz,2 Yasmin Rehman,3 Mohammad Salman,4 Shahid A Sami5

Department of Pathology & Microbiology,1-4 Department of Surgery,5 The Aga Khan University Hospital, Karachi, Pakistan.

Abstract

Objective: To determine the frequency of Heparin Induced Thrombocytopenia (HIT) in patients undergoing
elective cardiac bypass surgeries and to observe the platelets evolution post surgically in these patients.
Method: A prospective study was designed and 100 unselected consecutive patients undergoing elective
cardiac bypass surgery were enrolled and evaluated . The clinical and laboratory details were noted before and
after surgery. Their platelet counts were observed from day 0 (prior to surgery) to day 5 post operatively. Particle
gel immunoassay was used to demonstrate the presence of antibodies against heparin-platelet factor 4
complexes.
Results: There were 86 males and 14 females with median age of 59 and 53.5 years respectively. Marked
platelet count variation was detected during post operative period in all patients (n=100) ranging from 23 ±
SD186.73 to 389 ± 84.12 X 109/L. However, 20 patients showed >50% drop on day 5 and seven of these also
showed seroconversion. The clinical scoring for HIT was found to have a good negative predictive value.
Thromboembolic complications were not observed in any of our patients.
Conclusions: HIT is prevalent to a significant extent in patients after cardiac surgery in our clinical setting though
it mostly remains undetected and is an under-diagnosed entity. (JPMA 59:345; 2009)

Introduction

Heparin induced thrombocytopenia (HIT) Type II is
a life threatening pro-thrombotic complication of heparin
treatment resulting from immunoglobulin G (IgG)
antibodies that bind to platelet Fc RIIA receptors inducing
platelet activation with subsequent thrombocytopenia,
thrombin generation and endothelial cells injury.1 In sharp
contrast, HIT type I is a benign reversible disorder with mild
thrombocytopenia where platelet counts often recover in
spite of continued heparin treatment.2 Typically, onset of
immune mediated thrombocytopenia is observed after 5
days of heparin exposure and may either resolve within a
fortnight of drug discontinuation but such platelet recovery
may be delayed for months in some patients.2
HIT type II has been reported in both surgical and
medical settings. HIT occurs in up to 5% of orthopaedic
surgery patients, 3% of cardiac surgery patients, more than
1% of vascular surgery patients and 1% of medical patients
receiving therapeutic doses of unfractionated heparin.3 The
reasons for these variations are unknown but could be
related to different heparin preparations, patient population
dependent factors or even different laboratory techniques
used in detection of HIT associated antibodies. Patients
undergoing cardiac surgery on cardiopulmonary bypass
(CPB) have inherent risk of strong platelet activation due to
release of large amounts of platelet factor 4 (PF4) in their
plasma.4 Additionally, exposure to large doses of
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unfractionated heparin makes these patients unduly
susceptible to HIT.5 This perhaps is the reason of
development of HIT associated antibodies in nearly 50% of
them.6 In spite of this seroconversion, clinical
manifestations of HIT are observed in only 3% of CPB
patients.6
Heparin-induced thrombocytopenia should be
viewed as a clinicopathologic syndrome, that is, the
diagnosis should be made only if clinical abnormalities are
seen and HIT antibodies are detected.7 The clinical criteria
include exposure to unfractionated or low molecular weight
heparin, thrombocytopenia or a 50% decrease in baseline
platelet count, exclusion of other causes of
thrombocytopenia
(e.g.
medications,
infections,
disseminated intravascular coagulation), presence or
absence of thrombosis, atypical features in a minority of
cases (e.g. skin lesions, systemic reactions to heparin), and
recovery of thrombocytopenia after cessation of heparin
exposure.8 In vitro demonstration of heparin-platelet factor
4 antibodies (H-PF4) can be done through various
functional and immunological assays.9 Although the former
tests (serotonin release and platelet aggregation assay and
flow cytometry) are more specific and gold standard for the
diagnosis of HIT but they at the same time are also
technically demanding. In contrast, commercially available
antigen essays (e.g. enzyme linked immonosorbent assay
tests [ELISA] or particle gel immunoassay) are rapid and
user-friendly with ability to detect antibodies (IgG, IgM and
J Pak Med Assoc

IgA classes) that bind to PF4/heparin or
PF4/polyvinylsulfate complexes bound to a solid phase.
This study was designed to determine the frequency of
HIT in patients undergoing elective cardiac surgery on
cardiopulmonary bypass and to correlate HIT with the trend in
platelet count during immediate post operative period.

Patients and Methods

This was a prospective study conducted between
September 2006 and August 2007 at Aga Khan University
Hospital. We enrolled 100 unselected consecutive patients
undergoing elective on-pump cardiac surgery in the study after
approval from institutional ethical review committee and
informed consent of the patients. Clinical details for each
enrolled patient were carefully recorded with special emphasis
on any previous exposure to unfractionated (UFH) or low
molecular weight heparin (LMWH). Patients having
thrombocytopenia (platelet count <100X109/L) or
thrombocytosis (platelet count >450 x 109/L) at the start of
study were not registered. Similarly patients with any
underlying malignancy, or those receiving chemotherapy or
radiotherapy were also excluded.
Dosage and type of heparin received during and after
surgery was also noted.

Blood samples were collected from each patient in gel
tube (BD, Becton Dickinson and Company, New Jersey, USA)
for detection of H-PF4 antibodies and in EDTA container (5.0
ml in each) for platelet counts. Briefly, platelet count was
determined in each patient pre-operatively and on 3rd and 5th
post operative day. The platelet counts were repeated if
considered necessary at any time during their 7 days hospital
stay or during their subsequent follow-up. Their sera were
tested for H-PF4 antibodies prior to and during 5-7 days after
surgery.
A particle gel immunoassay ID-Heparin/PF4
antibody test (ID-HPF4) (DiaMed, Cressier sur Morat,
Switzerland) was utilized for the detection of antibodies to
heparin-PF4 complexes. Briefly, 10µL of test serum was
added to 50µL of pre-prepared suspension of red high
density polystyrene beads coated with heparin-PF4
complexes into the reaction chamber containing a buffered
sephacryl gel matrix and incubated for 5 minutes at room
temperature followed by centrifugation in ID centrifuge. HPF4 antibodies were detected by agglutinated beads either
on top or being dispersed through the gel matrix. A positive
test was repeated to ensure consistency of results. In
addition, complete blood count was performed for each
patient by Coulter Gen-S (Coulter Electronics, Fullerton,
CA, USA) and Leishman stained peripheral film was also
examined by experienced technologists and haematologists
to rule out pseudo thrombocytopenia. Prothrombin time

Vol. 59, No. 6, June 2009

(PT), activated partial thromboplastin time (APTT) and
plasma glucose levels were retrieved from our hospital
based computerized data system.

Anticoagulation for cardiopulmonary bypass was
achieved with bolus intravenous infusion of 400 units/kg of
sodium UFH (porcine) just before cardiac intervention.
Additional heparin was administered with continuous IV
infusion with the aim to keep activated clotting time (measured
through Medtronic ACT II) above 500 seconds during surgery
by monitoring the test at half hourly interval. LMWH was not
received by any patient. On completion of surgery, reversal of
heparinization was accomplished through intravenous infusion
of protamine sulphate. The mean duration of CPB for patients
was 1.45 hours. The patients were further anticoagulated after
surgery only if INR was <2.0 and patient had undergone an
additional valve replacement. This was achieved with
continuous heparin infusion.

The accepted criteria for the diagnosis of HIT type II8
is different from that described for CPB.10 Accordingly, we
considered a normal pattern of PC if the counts returned to
normal within 5-6 days of surgery. A diagnosis of HIT was
considered by either a decrease in PC that follows a previous
correction of thrombocytopenia occurring during CPB (pattern
a) or a persistently low PC in the days following surgery
(pattern b). Laboratory evidence for the presence of circulating
HIT antibodies was also determined. Clinical records were
observed by two subjects individually to determine the patterns
of platelet drop post surgically. Clinical probability of heparin
induced thrombocytopenia was calculated objectively through
Greinacher scoring system.11 Additionally, Warkentin and
Heddle score system12 was also utilized to determine the same.
In the first system three categories are defined: unlikely (score
0-3), probable (score 4, 5) and highly probable or definite
(score 6 or more) while in later the scores are: 6-8 (high), 4-5
(intermediate) and 0-3 (low).

SPSS statistical software Version 16.0 (SPSS Inc.,
Chicago, IL, USA) was used for statistical analysis. Two
tailed probability test (Mann-Whitney) and paired t test
were utilized where considered necessary to compare
groups. Level of significance was 0.05. Comparisons
between HIT and no- HIT subgroups were made using
stepwise logistic regression analysis.

Results

We evaluated 100 unselected consecutive patients
undergoing CPB including 14 females (median age 59 years,
range 45 to 73) and 86 males (median age 53.5, range 52 to 56)
for heparin induced thrombocytopenia. Of these, 4 patients
underwent an additional valve replacement or repair procedure.
Co-morbids like hypertension, diabetes and ischaemic heart
disease was present in 43, 47 and 21 patients respectively. Of
346

100 patients that were enrolled, only 19 did not have significant
family history for associated medical problems. Physical
examination was unremarkable in all patients.

Prior to surgery, laboratory investigations showed;
platelet count 224.79±80.79 x 109/L (range 100 - 411 109/L),
random blood sugar levels 139.48±61.73mg/dl (range 70339mg/dl) while prothrombin (PT) and activated partial
thrombin times (APTT) were 12.31±2.15 (range 10.30-31.80)
and 26.83±2.98 (range 20.0-40.00) seconds respectively.
Gender wise demographics and clinical details of patients did
not show any statistically significant variable with respect to
sex (data not shown).

Platelet drop:

Marked platelet count variation was detected during
post operative period in all patients (n=100) ranging from 23 ±
186.73 to 389 ± 84.12 X 109/L. Sixteen patients showed more
than 50% drop in their platelet count from their baseline on day
3 while another four patients did so in next two days. Hence
there were 20 patients on day 5 who showed >50% decline in
their platelet count. Their platelet counts (X 109/L) on day 0
were 100-411 (269±93.299) while on day 5 were 23-182
(92.80±46.385). Seven of these patients were positive for HPF4 antibodies. Percentage drop of platelet counts post
operatively is summarized in Table 1 and Figure. This shows
Table 1: Number of CPB patients with platelet trend during
immediate post op stay (n=100).
Platelet drop

n

Day 0

Day 5

p-value

>50 % decrease*
30-50% decrease
Normal
Low platelets

20
11
53
16

100-411(269±93)
170-411(280±80)
150-389(225±58)
103-148(123±15)

23-182(92±46)
89-269(170±51)
150-389(241±62)
65-250(127±50)

0.000
0.000
0.000
0.848

*The group includes one patient from low pre-operative platelet count.

that there was statistically significant difference in platelet drop
in 31 patients showing either >50% drop (n=20) or 3050%drop from their baseline (n=11). There were 53 patients
who had normal platelets to begin with and they showed a
statistically significant rise in their platelet counts on day 5.
There were 16 patients who had low platelet count
(<150X109/L) preoperatively and showed a rising trend
postoperatively though not statistically significant. The patients
with platelet drop were also evaluated for other co-existing
causes of thrombocytopenia such as septicaemia, drugs and
massive blood transfusion through logistic regression analysis
(data not shown). None of these were identified as a possible
etiology in any of the patients.

Frequency of H-PF4 antibodies:

All 100 patients were tested for H-PF4 antibodies
before and after surgery. Plasma samples from all patients
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Figure: Trend in the platelet counts in CPB patients showing 50% drop on 5th post
op day in patients with (group A; n=7) and without HIT antibodies (group B; n=13).
Group C (n=64) showed either 30-50% platelet dip or normal recovery. Data of 16
patients who had low platelet count at day 0 is not shown.

(100/100) were negative for these antibodies prior to surgery.
However, on day 5-7 post surgically, H-PF4 antibodies were
positive in seven patients (7%). All seven patients had >50%
decrease in their platelet counts on day 5 from their initial
baseline.

Clinical HIT and seroconversion:

We characterized our patients into two groups as per
criteria used by Pouplard et al in 2005.10 Accordingly, 64
patients were considered to be normal as all of them showed
recovery of their platelet count by day 5; 20 patients showed
a drop in platelet count during the surgical procedure and
failed to show recovery to normal values in the postoperative
period. Of these patients, 7 showed seroconversion as anti HPF4 antibodies were detected in their sera on day 5-7. There
were 16 patients with preoperative platelet count between
100-150X109/l who were not evaluated due to their lower
counts though seven of these patients did show a significant
drop in their platelet counts on day 5.
The clinical probability scorings for HIT as measured
through two systems: Warkentin and Heddle and
Greinacher11,12 are summarized in Table 2. It was observed that
patients who were diagnosed HIT on the basis of platelet
evolution (n=20) had statistically significant platelet drop in
post surgical period (p 0.000) and had probability scoring of
"high" (n=7) and "intermediate" (n=10) as per Warkentin
protocol and "likely" (n=7) and "unlikely" (n=13) according to
system devised by Greinacher. The first system was found to
better correlate with clinical HIT based on platelet evolution
than the second method. Moreover, both scoring systems were
found to have a good negative predictive value as all patients
J Pak Med Assoc

Table 2: Probability of Clinical HIT as determined through Pouplard platelet evolution, Warkentin and Greinacher scoring system. n=100.
Clinical Diagnosis

Day 0

Platelet Count

Day 5

Sig.(2-tailed)

HIT with seroconversion (n=7)

262.43±78.14

78.14±38.749

0.000

HIT without seroconversion (n=13)

262.50±86.70

103.33±33.950

0.000

Normal platelet evolution (n=64)

240.78±69.336

232.95±61.632

0.443

Low platelet counts on Day 0(n=16)

122.47±16.394

116.29±57.343

0.669

*Data not analyzed for scoring.

who had normal platelet recovery after CPB were identified to
have "low" score by Warkentin and were predicted as
"unlikely" by Greinacher. No statistically significant difference
was observed in patients with HIT (n=20) and HIT (n=64) had
no association with age and gender.

Thromboembolic complications:

No thromboembolic phenomenon was observed in any
patient in the immediate post operative period. Also, none of
the patients developed skin necrosis or systemic reaction to
heparin.

Discussion

The number of cardiac by pass surgeries performed in
our institute is estimated to be 750 annually. A number of
patients were assessed to be thrombocytopenic after cardiac
surgery but etiology of low platelets was never formally
evaluated in our clinical setting. This study was designed to
evaluate the frequency of typical onset HIT during on pump
elective CPB after exposure to UFH.

It has been observed that a significant number of CPB
patients demonstrate transient thrombocytopenia post
surgically due to haemodilution and/or platelet activation from
contact of blood with extracorporeal circuit.13 Immune
mediated HIT can further complicate the scenario by inducing
thrombocytopenia with paradoxical life threatening
thrombosis. Three different clinical presentations have been
described: rapid, typical, and delayed onsets HIT where
platelets drop begin respectively at day 1, 5 -14, and 9-40 after
cardiac surgery.14
A very variable incidence of typical onset HIT ranging
from 29% to 61% has been documented in CPB patients.15 We
diagnosed HIT clinically in 19 patients according to platelet
evolution as described previously.10 However, only 7 of these
had serological evidence of HIT. There may be several reasons
for the low frequency of HIT as observed by us: absence of
prior exposure to heparin within 100 days before CPB (except
2 patients), administration of relatively small dosage of heparin
Vol. 59, No. 6, June 2009

Warkentin
Low 0
Intermediate 4
High 3
Low 3
Intermediate 6
High 4
Low 64
Intermediate 0
High 0
*

Greinacher
Unlikely 4
Likely 3
Definite 0
Unlikely 9
Likely 4
Definite 0
Unlikely 64
Likely 0
Definite 0
*

during surgery and evaluation of H-PF4 antibodies during day
5-7 only. In addition, methodology for detection of HIT
associated antibodies in this study was also dissimilar to that
used in other studies.

We utilized particle gel immunoassay for anti H-PF4
antibodies for detection of HIT associated antibodies. The
reason for this choice may be convenience, decrease turn
around time and technical simplicity. Although functional
assay like 14C-Serotonin release assay (SRA) is considered to
be gold standard and is specific for the detection of HIT
antibodies,9 the requisite technical sophistication for this test
restricted us from such work up. Commercial PF4/polyanion
enzyme immunoassay are sensitive for detection of HIT
antibodies though they are less specific as may be detectable in
50% of CPB patients after one week of surgery. Moreover
results of ID-HPF4 had been observed to be comparable to
functional assays like SRA and heparin induced platelet
aggregation assay (HIPA) tests16 with an impressive sensitivity
of 94%.17 However, it is recommended that gel test should be
used in combination with a functional assay as other antigens
involved in HIT such as interleukin 8 or neutrophil-activating
peptide 2 may not be detected by it.18

Monitoring of platelet counts is an important critical
requirement of post cardiac surgical care to enable the early
diagnosis of HIT. In our experience, 64 of 100 patients
demonstrated lowering of their platelet count from initial
baseline on day 3-5 and patients who developed anti H-PF4
antibodies had platelet count ranging from 23-124 (mean 77.43
± 39.85). We found that a drop of >50% platelet on post day 5
irrespective of initial baseline count was closely associated
with the development of H-PF4 antibodies. Although median
platelet count reported in HIT associated with cardiac surgery
was as low as 55-60 x 109/L,19 however 10% of such patients
never show a platelet nadir of less than 150 x 109/L which may
be because HIT complicates a postoperative course that would
otherwise be characterized by thrombocytosis.10 Pouplard et al
in 200510 studied 305 patients with cardiac intervention and
noted an incidence of 53.4% HIT with platelet drop of 50%
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during day 8-11.

Patients with HIT (n=20) were classified as having
"probable" or "intermediate" and "high risk" for HIT by
Greinacher and, Warkentin and Heddle Scoring systems
respectively. However, 13 /20 patients were "unlikely" to have
HIT according to Greinacher.11 We found this system more
difficult to use and correctly apply to our patients as platelet
recovery within 10 days as required by the scoring system
could not be evaluated. Both systems correlated very well in
normal patients (without HIT) where scoring was either
"unlikely" or "low". Hence these systems were found to have
excellent negative predictive value.

Generally, heparin induced thrombocytopenia is
strongly associated with venous and arterial thrombosis. About
40%-50% patients with thrombocytopenia alone (isolated HIT)
will eventually develop a thrombotic event.20 The overall
thrombotic risk is very variable and has been related to the
severity of platelet decline ranging from 50% in mildly
thrombocytopenic patients (platelet nadir >100 x 109/L) to
90% in patients with severe thrombocytopenia (platelet nadir,
<30 x 109/L).21 In sharp contrast, thrombotic events are not that
frequently reported in cardiac surgery. Visentin et al21 in 1996
found an incidence of 61% HIT in CPB but did not observed
thromboembolic complication in any of his patients. Similarly,
Pouplard et al10 in 2005 reported aortic thrombosis in only one
of 305 cardiac surgery patients. Occasional cases of thrombosis
in CPB have been reported by a few.22-24 In our experience,
five of seven patients who developed H-PF4 antibodies had
mean platelet count of 99.2 ± 17.58 while remaining two had
23X109/L. In spite of these low platelet counts, none of them
had any thrombotic episode. This may be associated to genetic
variation related to our population. A study on 389 patients
with HIT, FcγIIa genotype was identified as the risk factor for
developing HIT associated antibodies and thrombotic
complications.25

Limitations of Study:

Earlier discharge of patient after cardiac surgery makes
prompt recognition of HIT difficult. Consequently, we could
not evaluate for typical onset HIT beginning after that time.

HPF4 ELISA detecting IgG only and C14 serotonin
release assays have high sensitivity and specificity
respectively. However, these tests were not utilized during the
study as they are technically demanding and are not available
in our set up or in any reference laboratory of our country.

Conclusions

This study demonstrates that heparin induced
thrombocytopenia is a relatively common adverse effect of
unfractionated heparin therapy during cardiopulmonary bypass
surgery in our setting. Careful follow-up of platelet counts may
identify patients who will eventually develop HIT antibodies.
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Larger prospective studies are needed to evaluate true
dimensions of the disease utilizing sophisticated tests. There is
also a need to study the various polymorphisms linked to
genetic variation with the possible development of HIT
associated antibodies.
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